GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

Home
/
update
/
details

MGI Tech and SeqOne Collaborate to Enhance Comprehensive Genomic Analysis

NextEdge Admin

17 Jun 2024

3 min 1 sec

MGI Tech Co., Ltd. and SeqOne have announced a strategic collaboration aimed at advancing genomic analysis solutions tailored for Human Genetics and Pathology labs worldwide. The partnership focuses on three key initiatives designed to integrate cutting-edge technologies and enhance diagnostic capabilities.

Firstly, the collaboration seeks to validate an end-to-end genomic analysis solution using MGI's DNBSEQ-G99 sequencing platform. This initiative aims to automate and streamline the Human Resource Deficiency (HRD) signature process, leveraging SeqOne's somaHRD solution. By combining Agilent Technologies' panels and Magnis lib prep automation, the workflow aims to deliver efficient and cost-effective HRD testing, including Genomic Instability score and BRCA testing.

Secondly, the partnership aims to enable SeqOne's AI-driven tertiary analysis solutions to work seamlessly with MGI's Megabolt platform. Megabolt, known for its bioinformatics acceleration capabilities, will integrate with SeqOne's variants identification and analysis solution. This integration targets Human Genetics labs, promising a versatile, intuitive, and time-saving pathway from sample analysis to reporting.

Thirdly, the collaboration will validate SeqOne's CE-IVD Platform for Germline and Somatic analysis, ensuring compatibility with MGI's sequencing data. This technical validation project focuses on assessing variant calling performance, quality control, sensitivity, and precision using reference control samples. The goal is to enhance the diagnostic accuracy and reliability of bioinformatic analyses in routine diagnostics.

Dr. Yong Hou, General Manager of MGI Europe and Africa, emphasized the collaboration's potential to deliver personalized healthcare solutions by combining MGI's advanced sequencing technology with SeqOne's genomic analysis platform. Martin Dubuc, CEO of SeqOne, highlighted the partnership's commitment to expanding access to sophisticated genomic analysis globally, aiming to improve healthcare outcomes through enhanced research and diagnostic capabilities.

Overall, the collaboration between MGI and SeqOne represents a significant step forward in integrating state-of-the-art sequencing technologies with advanced bioinformatics solutions, poised to empower clinicians with the tools needed for precision medicine and personalized patient care.